Trends in gastrointestinal cancer and metabolic syndrome mortality in the US (1999–2023).

M Maryam Nasir (6Ameer-ud-din Medical College, Lahore, Pakistan) A Abdullah Zia (6Ameer-ud-din Medical College, Lahore, Pakistan) A Aman Ullah F Faizan Ahmed O Omar Kamel (South valley university, Sohag, Egypt) S Sherif Eltawansy M Mushood Ahmed M Mohamed Bakr (Jersey Shore, New Jersey, NJ) H Hira Zahid (Dow Medical College, Karachi, Pakistan) K Kainat Aman (Batterjaee Medical College, Jeddah, Saudi Arabia) Y Yasir Rashid (Rai Medical College, Sargodha, Punjab, Pakistan) T Tehmasp Mirza (Shalamar Medical and Dental College, Lahore, Pakistan) N Najam Gohar (Ameer-ud-Din Medical College, Sialkot, Pakistan) A Areehah Zafar Masood (Ziauddin Medical University, Karachi, Pakistan) Y Yusra Junaid (Dow Medical College, Karachi, Pakistan) I Izzah Nayyab (Allama Iqbal Medical College, Lahore, Pakistan) H Husnain Ahmad (Shalamar Medical and Dental College, Lahore, Pakistan) M Muhammad Faizan Ali (Jinnah Postgraduate Medical Center, Karachi, Pakistan) F Faseeh Haider (9Allama Iqbal Medical College, Lahore, Pakistan) F Fatima Binte Athar (7Karachi Medical and Dental College, Karachi, Pakistan)

Abstract

e23054 Background: Gastrointestinal (GIT) cancers and metabolic syndrome contribute significantly to mortality. This study examines trends in mortality from 1999 to 2023, stratified by demographic and geographic factors to identify disparities. Methods: CDC WONDER data for U.S. adults aged 25+ from 1999 to 2023 were analyzed. Age-adjusted mortality rates (AAMRs) per million were calculated across gender, race, age groups, and census regions. Trends were evaluated using Joinpoint regression to compute average annual percentage change (AAPC) with 95% confidence intervals (CIs) and p-values. Results: GIT cancers and metabolic syndrome caused 468,086 deaths from 1999 to 2023. AAMRs rose from 63/million (95% CI 61.83–64.17) in 1999 to 105.31/million (95% CI 104.1–106.52) in 2023 (AAPC: 1.95%; 95% CI 1.67–2.29; p < 0.000001). Males had higher mortality (259,865 deaths; AAMR: 102.04/million) than females (208,221 deaths; AAMR: 61.77/million), with AAPCs of 2.13% (95% CI 1.89–2.44; p < 0.000001) and 1.59% (95% CI 1.26–1.99; p < 0.000001), respectively. Blacks and American Indians had the highest AAMRs (122.19/million and 96.34/million, respectively). Whites showed the steepest AAMR increase (AAPC: 2.46%; 95% CI 2.12–2.88; p < 0.000001). Adults aged 75+ exhibited the highest AAMR (605.61/million, 2021–2023; AAPC: 1.64%; 95% CI 1.30–2.00; p < 0.000001). The South had the highest mortality (172,025 deaths; AAMR: 124.11/million in 2023) and the most pronounced increase (AAPC: 3.53%; 95% CI 3.19–4.03; p < 0.000001). Conclusions: Mortality from GIT cancers and metabolic syndrome has risen significantly, with disparities by gender, race, and geography. Targeted public health interventions are urgently needed, especially for males, Blacks, and residents of the South. Cohort Age Adjusted Mortality Rate per million Average Annual Percentage Change 95% Confidence Interval P- Value 1999-2020 2021-2023 Overall 79.45 104.37 1.9487* 1.6682 to 2.2871 < 0.000001 Males 102.04 137.47 2.1346* 1.8893 to 2.4377 < 0.000001 Females 61.77 77.09 1.5854* 1.2637 to 1.9942 < 0.000001 American Indian or Alaska Native 96.34 124.87 1.9041* 1.3074 to 2.7395 < 0.000001 Asian or Pacific Islander 75.19 77.7 -0.1557 -0.4393 - 0.1992 0.375125 Black or African American 122.19 137.13 0.7840* 0.3367 to 1.4804 0.003199 White 73.39 104.7 2.4611* 2.12 to 2.8801 < 0.000001 Hispanic or Latino 89.73 106.44 1.2193* 0.904 to 1.6191 < 0.000001 Ages 25-54 5.77 10.19 4.3353* 3.9483 to 4.7028 < 0.000001 Ages 55-74 122.59 173.1 2.3220* 2.1322 to 2.5572 < 0.000001 Ages 75+ 498.5 605.61 1.6373* 1.3026 to 2.0005 < 0.000001 Northeast 73.46 77.78 0.5468* 0.2972 to 0.8622 0.002799 Midwest 83.69 97.23 0.9622* 0.6677 to 1.2643 < 0.000001 South 101.6 119.65 3.5338* 3.1858 to 4.0287 < 0.000001 West 85.19 106.91 1.6154* 1.325 to 1.9785 < 0.000001

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (20)

M

Maryam Nasir

6Ameer-ud-din Medical College, Lahore, Pakistan

A

Abdullah Zia

6Ameer-ud-din Medical College, Lahore, Pakistan

A

Aman Ullah

F

Faizan Ahmed

O

Omar Kamel

South valley university, Sohag, Egypt

S

Sherif Eltawansy

M

Mushood Ahmed

M

Mohamed Bakr

Jersey Shore, New Jersey, NJ

H

Hira Zahid

Dow Medical College, Karachi, Pakistan

K

Kainat Aman

Batterjaee Medical College, Jeddah, Saudi Arabia

Y

Yasir Rashid

Rai Medical College, Sargodha, Punjab, Pakistan

T

Tehmasp Mirza

Shalamar Medical and Dental College, Lahore, Pakistan

N

Najam Gohar

Ameer-ud-Din Medical College, Sialkot, Pakistan

A

Areehah Zafar Masood

Ziauddin Medical University, Karachi, Pakistan

Y

Yusra Junaid

Dow Medical College, Karachi, Pakistan

I

Izzah Nayyab

Allama Iqbal Medical College, Lahore, Pakistan

H

Husnain Ahmad

Shalamar Medical and Dental College, Lahore, Pakistan

M

Muhammad Faizan Ali

Jinnah Postgraduate Medical Center, Karachi, Pakistan

F

Faseeh Haider

9Allama Iqbal Medical College, Lahore, Pakistan

F

Fatima Binte Athar

7Karachi Medical and Dental College, Karachi, Pakistan